Novartis to buy Avidity Biosciences for $12bn

Financial TimesSunday, October 26, 2025 at 5:35:01 PM
Novartis to buy Avidity Biosciences for $12bn
Novartis has announced its acquisition of Avidity Biosciences for $12 billion, marking a significant move in the pharmaceutical industry. This deal, the largest under CEO Vas Narasimhan, highlights Novartis's commitment to expanding its portfolio in rare diseases, an area that has seen increasing demand for innovative treatments. The acquisition not only strengthens Novartis's position in the market but also promises to enhance patient care for those affected by rare conditions.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Novartis to buy US-listed Avidity Biosciences for $12 bln
PositiveFinancial Markets
Novartis has announced its acquisition of Avidity Biosciences for $12 billion, marking a significant move in the biotechnology sector. This deal is expected to enhance Novartis's portfolio and strengthen its position in the pharmaceutical market, particularly in innovative therapies. The acquisition highlights the growing trend of large pharmaceutical companies investing in biotech firms to access cutting-edge technologies and treatments, which could lead to improved patient outcomes.
Novartis to acquire Avidity Biosciences for about $12 billion
PositiveFinancial Markets
Novartis has announced its plan to acquire Avidity Biosciences for approximately $12 billion, a move that highlights Novartis's commitment to expanding its portfolio in the biotechnology sector. This acquisition is significant as it not only strengthens Novartis's position in the market but also enhances its capabilities in developing innovative therapies, potentially benefiting patients with unmet medical needs.
Novartis to acquire Avidity Biosciences for $12 billion
PositiveFinancial Markets
Novartis has announced its plan to acquire Avidity Biosciences for $12 billion, a move that highlights its commitment to expanding its portfolio in the biotechnology sector. This acquisition is significant as it allows Novartis to enhance its capabilities in developing innovative therapies, particularly in the field of RNA-targeted treatments. The deal reflects the growing trend of large pharmaceutical companies investing in biotech firms to stay competitive and meet the evolving needs of patients.
Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports
PositiveFinancial Markets
Novartis is reportedly close to finalizing a deal to acquire Avidity Biosciences for more than $70 per share, according to Bloomberg News. This acquisition could significantly enhance Novartis's portfolio in the biotechnology sector, allowing them to leverage Avidity's innovative technologies and research capabilities. Such a move not only reflects Novartis's commitment to expanding its reach in the market but also highlights the growing interest in gene therapies and RNA-targeted treatments.
Avidity Biosciences (RNA) CMO Hughes sells $105k in stock
NeutralFinancial Markets
Avidity Biosciences' Chief Medical Officer, Hughes, has sold $105,000 worth of stock. This transaction is noteworthy as it reflects the ongoing activities of company executives in managing their personal investments. While stock sales by executives can sometimes raise eyebrows, they are often part of regular financial planning. Investors will be watching closely to see how this might impact the company's future performance.
Latest from Financial Markets
Australia takes Microsoft to court, says it misled 2.7 million customers
NegativeFinancial Markets
Australia has initiated legal proceedings against Microsoft, alleging that the tech giant misled approximately 2.7 million customers regarding its products and services. This case is significant as it highlights the ongoing scrutiny of large corporations and their accountability to consumers, potentially setting a precedent for how tech companies communicate with their users.
Dow futures jump 300 points as U.S.-China trade war heads for ceasefire while Wall Street eyes another Fed rate cut and earnings from AI giants
PositiveFinancial Markets
Dow futures surged by 300 points as optimism grows over a potential ceasefire in the U.S.-China trade war. This positive momentum is further fueled by Wall Street's anticipation of another Federal Reserve rate cut and upcoming earnings reports from major tech companies like Meta, Microsoft, and Alphabet. With Apple and Amazon also set to report soon, investors are hopeful that these earnings will reflect strong performance, which could bolster market confidence and economic stability.
Earnings call transcript: Perseus Mining Q1 2025 sees strong gold production
PositiveFinancial Markets
Perseus Mining has reported strong gold production in its Q1 2025 earnings call, showcasing the company's robust operational performance. This positive trend is significant as it reflects the company's ability to navigate market challenges and capitalize on opportunities, which could lead to increased investor confidence and potential growth in the mining sector.
POET Technologies raises $150 million in registered direct offering
PositiveFinancial Markets
POET Technologies has successfully raised $150 million through a registered direct offering, marking a significant milestone for the company. This influx of capital is expected to bolster its growth initiatives and enhance its technological advancements, which is crucial in the competitive tech landscape. Investors are optimistic about the potential returns, making this a noteworthy development in the tech sector.
Walmart Just Fired A Big AI Shot Across Amazon’s Bow
PositiveFinancial Markets
Walmart's collaboration with OpenAI to integrate AI-powered shopping into ChatGPT marks a significant shift in the retail landscape, directly challenging Amazon's dominance. This partnership not only enhances the shopping experience for consumers but also sets a new standard for how retailers can leverage technology to improve search and discovery. As AI continues to evolve, this move could reshape competition in the retail sector, making it an exciting development for both companies and shoppers alike.
UK Chancellor to Press for Gulf Trade Deal in Riyadh Visit
PositiveFinancial Markets
UK Chancellor Rachel Reeves is heading to Saudi Arabia to push for a trade deal with Gulf states, aiming to enhance the UK's economic growth ahead of her important budget announcement. This visit is significant as it highlights the UK's commitment to strengthening international trade relationships, which could lead to increased investment and economic opportunities.